Now that 2023 is well underway, it's time to reflect on H.M. Pharma Consultancy's 2022. (Yes, we postponed this a little so that everyone else could submit his reviews.) Serving our customers, wrapping up REPO-TRIAL... What a year it has been, too! In addition to preparing chemistry, manufacturing, and control (CMC) documentation for several substances that are now undergoing clinical trials, HM...

Vienna and Gleinstätten, August 2, 2022 – REPO4EU will commence a month from now. Above and beyond several other tasks, this 5+ year Horizon Europe project will develop a generic framework that can be used by anybody who wishes to start a drug repurposing project according to current best practices. From in silico discovery to regulatory issues and healthcare provider perspectives, every aspect wi...

The H2020 EU project REPOTRIAL is approaching its final year. This is a good time to share what we have already achieved –although the most significant news are expected only during the first half of 2023, when the phase II clinical studies are finalized, or near completion. Our European consortium is exploring new ways to treat two conditions with a high unmet medical need – acute ischemic strok...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are shortened from the published ones. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be con...

H.M. Pharma Consultancy is building a new tool: a database of drug repurposing claims, suggestions, and developments. For the moment we are attempting to capture and link everything of relevance that has been published since 2010, and we also integrate whatever earlier material we detect. At the heart of this effort is the collection of drug repurposing patent applications that we have captured –...